ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 568

Pneumococcal Polysaccharide Vaccination Regulates T and B Lymphocyte Cytokine Responses and Decreases Kidney Stat1 Levels In MRL/Lpr Mice In Vivo

Victor Gazivoda1, Shikha Mehta2, Luhan Wang3, Julia Ash4, Kirk E. Sperber3 and Ioannis Tassiulas3, 1Medicine, New York Medical College, Valhalla, NY, 2New York Medical College, Valhalla, NY, 3Medicine-Rheumatology, New York Medical College, Valhalla, NY, 4Rheumatology, New York Medical College, Valhalla, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells, cytokines and toll-like receptors, Lupus, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Zwitterionic polysaccharides can activate CD4+ T cells after processing and presentation by antigen-presenting cells. The 23-valent capsular polysaccharide pneumococcal vaccine, PneumoVax, protects against invasive pneumococcal pneumonia and is indicated for patients with chronic autoimmune diseases and/or on chronic immunosuppressive treatment. The effect of polysaccharide vaccines on the function of cellular immunity and the inflammatory response are not well defined. We studied the immunological effects of pneumococcal polysaccharide vaccination in the MRL/lpr mouse model of lupus, by analyzing the cytokine profile of activated T and B lymphocytes. We also analyzed the effect of polysaccharide vaccination on the expression of Stat1 in the kidney and brain, target organs of inflammation in this mouse model of lupus.

Methods: Eight week old MRL/lpr mice were purchased from Jackson Laboratories. The first group of mice (n=5) vaccinated with PneumoVax (0.5ml of a 23-valent unconjugated pneumococcal polysaccharide vaccine), the second group (n=5) received Mycophenolate mofetil (MMF) (100mg/kgr of body weight) in standard mouse chow, and the third group (n=5) was left untreated. Eight weeks after treatment the mice were sacrificed. T and B lymphocytes were isolated from the spleens. T cells were stimulated with soluble CD3/CD28 beads, PHA and plate bound polysaccharides. B lymphocytes were stimulated with plate bound IgM, plate bound polysaccharide, LPS and a R848. The culture supernatants of the stimulated lymphocytes were analyzed by specific ELISAs for cytokine production of IL-4, IFN-g, IL-17, IL-10, TNF-a and IL-6. Protein extracts were isolated from perfused kidneys. Stat1 and Stat3 protein levels from the extracts were analyzed with Western blotting.

Results: T lymphocytes from PneumoVax vaccinated mice showed differential regulation of cytokine production after CD3/CD28 stimulation, with complete block in IFN-g and IL-17 production compared with the non-vaccinated mice. CD3/CD28-induced IL-4 and TNF production by T cells did not differ in the two groups; however, IL-10 production was significantly increased in the vaccinated group. Interestingly, the decrease in T cell IFN-g and IL-17 production was comparable to the MMF treated group. B lymphocytes from PneumoVax vaccinated mice produced significantly decreased IL-6, IL-10 and TNF in response to plate bound IgM, LPS and R848 stimulation compared to the control group. Analysis of Stat1 protein levels in the kidneys, showed that PneumoVax vaccinated mice had significantly decreased expression compared with the control group, whereas Stat3 levels were not affected.

Conclusion: Pneumococcal polysaccharide vaccination preferentially modulates T and B lymphocyte cytokine responses, after antigen and pattern recognition receptor stimulation in the MRL/lpr mouse model of lupus. Moreover, the expression of Stat1 in the kidneys, a major target organ of inflammation in this model, was significantly decreased in the polysaccharide vaccinated animals. These results suggest that zwitterionic polysaccharides may have a role in re-establishing the immune and inflammatory homeostasis in chronic autoimmune/inflammatory conditions.


Disclosure:

V. Gazivoda,
None;

S. Mehta,
None;

L. Wang,
None;

J. Ash,
None;

K. E. Sperber,
None;

I. Tassiulas,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pneumococcal-polysaccharide-vaccination-regulates-t-and-b-lymphocyte-cytokine-responses-and-decreases-kidney-stat1-levels-in-mrllpr-mice-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology